Texaclear Pain Reliever Liquid
NDC Package 58809-389-08
Package Information
Texaclear Pain Reliever (caffeine, choline salicylate) liquids is do not take more than directed.adults and children 12 years of age and over: take 30mL every 6 hours, while symptoms persistdo not take exceed 4 doses in any 24 hours unless directed by a doctor children under 12 years of age: ask a doctor use enclosed dose cup. This formulation utilizes a liquid delivery system. Marketed by Gm Pharmaceuticals, Inc, this product is identified by NDC 58809-389 and is authorized under FDA application M013.
Identification & Billing
- RxCUI: 1994320 - caffeine 65 MG / choline salicylate 870 MG in 30 mL Oral Solution
- RxCUI: 1994320 - caffeine 2.17 MG/ML / choline salicylate 29 MG/ML Oral Solution
- RxCUI: 1994320 - caffeine 65 MG / choline salicylate 870 MG per 30 ML Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 58809 - Gm Pharmaceuticals, Inc
- 58809-389 - Texaclear Pain Reliever
- 58809-389-08 - 237 mL in 1 BOTTLE
- 58809-389 - Texaclear Pain Reliever
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 58809-389-08 identifies a specific commercial package of 237 ml in 1 bottle of Texaclear Pain Reliever, a human over the counter drug labeled by Gm Pharmaceuticals, Inc. This liquid is formulated for oral use and contains caffeine; choline salicylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gm Pharmaceuticals, Inc on December 14, 2017. The current certification is valid through December 31, 2026.
How is this Gm Pharmaceuticals, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 58809038908. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.